Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Jul

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Welcome and Introduction to Vi3C

Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer

FDA Releases Final Guidances to Expand Participation in Cancer Clinical Trials

Phase III Trial Finds No Benefit for Magrolimab Combination in Higher-Risk MDS

ELEVATE Trial Shows Disease-Free Survival Benefit With Adjuvant Ensartinib in ALK-Positive NSCLC

Dabrafenib Plus Trametinib Improves Progression-Free Survival in BRAF V600E-Positive Differentiated Thyroid Cancer